Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model

Blood

Volumn 107, Issue 2, 2006, Pages 655-660

  Menu, Eline ^b   Jernberg Wiklund, Helena ^b   Stromberg, Thomas ^b   De Raeve, Hendrik ^b   Girnita, Leonard ^b   Larsson, Olle ^b   Axelson, Magnus ^b   Asosingh, Kewal ^b   Nilsson, Kenneth ^b   Van Camp, Ben ^b   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; LIGNAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PARAPROTEIN; PICROPODOPHYLLIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL DISEASE; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW TUMOR; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROSIS; KAPLAN MEIER METHOD; LOW DRUG DOSE; MICROVASCULATURE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PERITONEAL DISEASE; PERITONITIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; STAINING;

EID: 30444446821     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0293     Document Type: Article

References (44)

1. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503-508.
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
3. Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992;80:2326-2335.
4. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
5. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991;77:2688-2693.
6. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994;84:2269-2277.
7. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712-3720.
8. Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma. 1993;9:441-452.
9. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-1478.
10. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
11. Van Valckenborgh E, De Raeve H, Devy L, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer. 2002;86:796-802.
12. Le Roith D, Bondy C, Yakar S, Liu J. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53-74.
13. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
14. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-877.
15. Abboud SL, Bethel CR, Aron DC. Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest. 1991;88:470-475.
16. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol. 2000;111:626-634.
17. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
18. Qiang YW, Kopantzev E, Rudikoff S. Insulin like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood. 2002;99:4138-4146.
19. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60:6763-6770.
20. Nilsson K, Georgii-Hemming P, Spets H, Jernberg-Wiklund H. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol. 1999;246:325-335.
21. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 1999;93:235-241.
22. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β1-integrin and phosphatidylinositol 3-kinase/Akt signalling. Cancer Res. 2003;63:5850-5858.
23. Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor 1 induces migration and invasion of human multiple myeloma cells. Blood. 2004;103:301-308.
24. Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer. 2004;90:1076-1083.
25. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004;64:236-242.
26. Radl J, De Glopper E, Schuit HRE, Zurcher C. Idiopathic paraproteinemia II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol. 1979;122:609-613.
27. Vanderkerken K, De Greef C, Asosingh K, et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer. 2000;82:953-959.
28. Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997;76:451-460.
29. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series, a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1:351-356.
30. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206.
31. Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. The F-actin content of multiple myeloma cells as a measure of their migration. Ann N Y Acad Sci. 2002;973:124-134.
32. Guttner J. Complications and effects of the intraperitoneal application in animal experiments. Pharmazie. 1975;30:129-133.
33. Standal T, Borset M, Lenhoff S, et al. Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. 2002;100:3925-3929.
34. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-518.
35. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001;54:133-137.
36. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63:5073-5083.
37. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003;63:8912-8921.
38. Bohula EA, Salisbury AJ, Sohail M, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003;278:15991-15997.
39. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 2004;279:5017-5024.
40. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231-239.
41. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221-230.
42. Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. Prepublished on September 15, 2005, as DOI 10.1182/blood-2005-01-0306. (Now available as Blood. 2006;107:669-678.
43. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 2004;23:7854-7862.
44. Asosingh K, Gunthert U, Bakkus MH, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res. 2000;60:3096-3104.